OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
May 01, 2008
Your guide to the world's top 50 pharma companies. The giants may be struggling, but even in a tough year, the industry's most successful companies know how to hit the bullseye.
In these cost cutting times, no drugmaker can afford to keep shoveling money down the Rebate Black Hole. Here's how to optimize your ROI and push back against the growing pressure of third-party rebates
Pharmacoactuarial analysis helps drug companies communicate value to health plans
Tracking business by indication is critical for evaluating market performance and making accurate resource allocations
Pharma can stand to win hearts, minds, and tax credits by launching an eco bandwagon
More patients are demanding drugs--and showing up everywhere form YouTube to the Supreme Court. But to offer access to investigational drugs, companies first need to know the rules
How do you find and license the best drugs out there? If you're Merck, you send scientists to go get 'em
Technology isn't the magic bullet, but it can help you hit your target
Your current backup and recovery strategy may be leaving you vulnerable to non-compliance, significant revenue loss, and negative brand exposure. Learn how to protect your business
The tech-savvy creative team at Concentric Rx has its sales force mixing work and play
Thanks to Dr. Google and Nurse Yahoo, pharma consumers know better than ever how to get exactly what they want
Promotional spending is down as companies rationalize and optimize budgets. But in contrast to big changes on the sales side, marketers are still trying to make the old model work
Meet the Korean pharma consumer: affluent, aging, and crazy about drugs
One company's program provides an interesting model for the future of DTP
How to stretch that portfolio to make ends meet
San Diego's booming biotech cluster searches for its future-and yours
FDA is being pressured to get its act together. The agency says it needs more money and more people to get approvals out the door
A plunging currency and other economic turmoil shouldn't phase pharma, right? Yes and no